TABLE 4.
Mean changes from baseline to 12 weeks of treatment in the monoamine neurotransmitters and several measurements by randomization group
| Variable | Quadruple combination | Placebo | Between‐group difference (95% CI) | p |
|---|---|---|---|---|
| Monoamine neurotransmitters | ||||
| Plasma serotonin, ng/ml | 117.4 ± 44.6* | 184.2 ± 46.2** | −66.7 (−195.6, 62.1) | .30 |
| Plasma norepinephrine, pg/ml | −36.0 ± 20.8 | −1.6 ± 20.8 | −34.4 (−93.9, 25.2) | .25 |
| Plasma dopamine, pg/ml | 1.55 ± 2.77 | −0.68 ± 2.77 | 2.23 (−5.63, 10.10) | .57 |
| Hemoglobin, g/L | −2.7 ± 2.7 | −4.5 ± 2.8 | 1.8 (−6.5, 10.0) | .66 |
| Blood biochemistry | ||||
| Fasting plasma glucose, mmol/L | −0.18 ± 0.12 | −0.11 ± 0.12 | −0.07 (−0.41, 0.27) | .68 |
| Serum potassium, mmol/L | −0.21 ± 0.07** | 0.07 ± 0.07 | −0.28 (−0.49, −0.08) | .009 |
| Serum total cholesterol, mmol/L | 0.11 ± 0.12 | −0.03 ± 0.12 | 0.14 (−0.19, 0.48) | .39 |
| Serum HDL cholesterol, mmol/L | −0.04 ± 0.03 | −0.05 ± 0.03 | 0.01 (−0.09, 0.10) | .88 |
| Serum triglycerides, mmol/L | 0.08 ± 0.17 | −0.16 ± 0.17 | 0.24 (−0.26, 0.74) | .33 |
| Serum creatinine, µmol/L | −1.3 ± 2.0 | 1.0 ± 1.8 | −2.3 (−7.9, 3.2) | .40 |
| Serum uric acid, µmol/L | 32.6 ± 14.8 | 6.6 ± 15.3 | 26.0 (−18.5, 70.5) | .45 |
| eGFR, ml/min/1.73 m2 | 3.9 ± 3.4 | −0.1 ± 3.2 | 4.1 (−5.5, 13.6) | .39 |
Values are least square mean ± standard error, unless otherwise indicated. eGFR indicates estimated glomerular filtration rate; HDL, high‐density lipoprotein.
Significance of the difference from baseline, * p < .05, ** p < .01.